Wockhardt profitability improves in FY26 on ₹888cr sales

Why Wockhardt’s profitability is back in focus

Wockhardt Ltd’s recent financial updates have brought the company’s profitability trend back into investor focus. The company has been reducing losses over time, while also posting a standout revenue quarter. The question investors are asking is simple: is the improvement sustainable or just a one-off jump. Data points across trailing twelve months, annual results, and the latest quarter show a clear direction of travel, even if the picture is not uniform across sources. The stock’s sharp price swings around result days also show how sensitive sentiment is to incremental changes in earnings.

Losses have narrowed across TTM, FY25, and FY24

On a trailing twelve-month (TTM) basis, Wockhardt’s net profit is reported at -₹10 crore. For the year ended March 2025, the net profit is cited at -₹47 crore, versus -₹463 crore for March 2024. That sequence indicates a meaningful narrowing of losses year-on-year. It also suggests the company is closer to breakeven at the consolidated level than it was a year ago. However, investors typically look for multiple quarters of consistent profitability before treating a turnaround as established.

December 2025 quarter: record revenue and sharp profit jump

In the quarter ended December 2025, Wockhardt reported net sales of ₹888 crore, described as the highest quarterly figure the company has recorded. Profit before tax excluding other income (PBT less OI) increased to ₹52 crore, stated as a 1,385.7% jump versus the average of the preceding four quarters. Net profit after tax (PAT) for the quarter was reported at ₹68.10 crore, cited as a 268.1% rise versus the prior four-quarter average. The narrative accompanying these numbers points to cost control and operating leverage supporting margin expansion. The same update also flags that competitive pressures in pharmaceuticals remain present.

Another Q3 profit read-through shows a smaller profit figure

A separate market note described Wockhardt as swinging back to a small profit in Q3 FY26, citing ~₹14 crore to ~₹20 crore net profit on ~₹721 crore revenue. Another report around the same period said the company posted ₹27.5 crore net profit for the third quarter, alongside revenue of ₹888 crore and revenue growth of 23%. These differences highlight that investors should watch the exact definition being used in each report (for example, standalone versus consolidated, or quarter mapping). What remains consistent across the reporting is that profitability improved versus the loss-making base of the prior year.

Operational signals: receivables efficiency improved

Beyond headline profit, Wockhardt’s operational metrics also moved in a supportive direction. The company’s debtors turnover ratio for the half-year period was reported at 5.57 times, described as the highest in recent years. Better receivables collection can directly support operating cash flow and reduce working capital intensity. For a pharma manufacturer, that can matter as much as accounting profits, particularly during periods of product investments and regulatory spending.

Stock reaction: gains around results, but sharp swings persist

Wockhardt’s share price has reacted strongly to quarterly updates. The stock closed at ₹1,428.70 on 11 February 2026, up 1.09% from ₹1,413.35, and traded between ₹1,388.05 and ₹1,456.90 that day. It remained below its 52-week high of ₹1,870.00 and above its 52-week low of ₹1,109.60. Another trading update noted the stock climbed 2.7% to ₹1,448.7 on February 10, while a separate session saw the stock trade around ₹1,546 with an intraday high of ₹1,566, compared with a prior close of ₹1,472. The company’s shares were also reported to have hit an all-time high of ₹1,809.95 during a 17% intraday rally on the BSE in another instance.

Snapshot table: key reported financial and operating datapoints

Annual revenue and loss: FY25 improved versus FY24

In a regulatory filing summary, Wockhardt reported FY25 net loss of -₹57 crore, improving from -₹472 crore in FY24. Revenue increased to ₹3,012 crore in FY25 from ₹2,798 crore in FY24. Separately, another dataset in the same information bundle cited total revenue of ₹3,074 crore for FY25 and ₹2,881 crore for FY24, which may reflect a different consolidation scope or classification. Either way, the direction reported is higher revenue and a substantially reduced loss.

Ratings and sentiment: mojo grade cut despite better quarter

Despite the positive quarterly profit narrative, the company’s mojo grade was downgraded from Hold to Sell on 5 January 2026. The financial trend parameter was described as shifting from “very positive” to “positive,” implying moderation rather than deterioration. The mojo score for financial performance fell to 17 from 23 over three months. This combination suggests that, while results improved, expectations and valuation sensitivity may have risen.

Market comparison: short-term outperformance, mixed longer snapshots

Relative performance data in the same update showed mixed outcomes. Over the past week, Wockhardt gained 5.70% versus the Sensex at 0.64%. Year-to-date, Wockhardt was down 1.19%, close to the Sensex decline of 1.11%. Longer horizon numbers were much stronger: a three-year return of 635.87% versus 38.88% for the Sensex, and a five-year return of 173.12% versus 64.25% for the benchmark. Another comparison in the same text also cited a one-year return of -6.15% for Wockhardt versus 9.01% for the Sensex, underlining volatility across measurement windows.

Regulatory and product catalyst: Zaynich update

One key catalyst mentioned alongside the rally was USFDA acceptance for Wockhardt’s Zaynich antibiotic, with a note that it received fast-track status. The company was also described as planning to launch Zaynich in India within the fiscal year and pursuing USFDA and EU filings during FY26. Market sizing was presented as $1 billion in the US and EU and ₹17,000 crore in India. While market size is not the same as addressable revenue, such updates tend to influence sentiment for research-led pharma names.

Conclusion

Wockhardt’s reported numbers point to improving profitability, led by a sharp quarterly rebound and a steady narrowing of annual and TTM losses. The record ₹888 crore quarterly sales print and improved working-capital efficiency strengthened the recovery narrative, even as external ratings turned more cautious. Investors will likely track the next set of quarterly results and regulatory milestones, including FY26 filing progress and the stated India launch timeline for Zaynich.